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INTRODUCTION
Genotype is increasingly recognized as an important factor
influencing the likelihood for drug effectiveness or risk for
adverse events. Genetic information is now included in
US Food and Drug Administration-approved labeling for
over 130 drugs, and in some cases, the information is in
the form of a boxed warning given the potentially serious
implications of genotype on drug response. Based on the
growing body of evidence supporting genetic contributions
to drug response, the Clinical Pharmacogenetics Implemen-
tation Consortium (CPIC) was formed to provide consensus
guidelines on interpretation and translation of genotype
results into actionable prescribing decisions.1 Guidelines
have been published for 18 drugs or drug classes as of late
2016. The Precision Medicine Initiative is expected to further
drive discoveries in genomic medicine and their translation
to patient care.2 In 2013, the National Institutes of Health
(NIH)-funded Implementing GeNomics In praTticE (IGNITE)
network was established to support the development and
investigation of genomic medicine practice models to
enhance its implementation into routine clinical practice.3
One of the challenges hindering genomic implementation
is the limited data on the outcomes and cost-effectiveness
of genotype-guided drug therapy. The IGNITE network,
consisting of institutions funded in the network and affiliate
members, includes a number of institutions that have imple-
mented pharmacogenetic testing to assist with prescribing
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decisions. This creates an opportunity for multiinstitu-
tional collaboration to share data and create a real-world
patient population of sufficient size to examine the impact
of implementing pharmacogenetic testing on important
clinical outcomes. Herein, we describe the IGNITE Phar-
macogenetics Working Group and the process for an initial
collaboration to examine a use case, namely, outcomes with
CYP2C19 genotype-guided antiplatelet therapy following
percutaneous coronary intervention (PCI). We also describe
how this initial collaboration provides the infrastructure for
ongoing and future collaborative work.
IGNITE PHARMACOGENETICS WORKING GROUP
The IGNITE Network and funded projects have been
described.3 While not all funded projects are related to phar-
macogenetics, all sites funded by the network and most affil-
iate members have implemented pharmacogenetic testing
in some regard. Following establishment of the IGNITE
Network in 2013, the Pharmacogenetics Working Group
was formed in January 2015 with the goals of broadly
engaging institutions (funded IGNITE sites and affiliate
members) implementing pharmacogenetics into practice to:
i) share and collectively disseminate data on implementation
strategies, metrics, and patient-related outcomes following
the utilization of genotype-guided therapy; and ii) examine
healthcare costs with pharmacogenetic implementation at
multiple institutions. The working group consists of the six
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Figure 1 Institutions participating in the IGNITE Pharmacogenetics Working Group. Blue dots represent funded institutions within the
IGNITE Network. Yellow dots represent affiliate members.
NIH-funded institutions within IGNITE, their collaborating
institutions, and nine affiliate members (Figure 1). The group
welcomes institutions that have established pharmacoge-
netic programs as well as those with newly implemented
programs or in the process of implementation. Gene–drug
pairs implemented at institutions within the interest group
are listed in Table 1. Each institution agreed to share clinical
implementation strategies with other institutions within
the network for potential adoption. In this regard, newer
programs may benefit from learning about and applying
implementation strategies (i.e., genotyping procedures and
clinical decision support) that have been successful at more
established institutions. In addition, each site agreed to
share patient-level data as appropriate for collective exam-
ination of patient-related outcomes with pharmacogenetic
implementation. Institutions in the process of implementa-
tion (and without current data) are able to fully participate in
conference calls and discussions, but have limited access
to data from other institutions.
The working group is led by investigators at the Univer-
sity of Florida, and members communicate through twice-
monthly conference calls, in-person meetings of the IGNITE
Network, and additional teleconferences for data analysis
and writing subgroups. Prior to participation in the work-
ing group, each institution signed a memorandum of under-
standing (MOU), adapted from the International Warfarin
Pharmacogenetics Consortium, and outlining responsibili-
ties of group members, requirements for access to compiled
data, and authorship policies. The MOU is available through
the SPARK toolbox on the IGNITE website (https://ignite-
genomics.org/spark-toolbox/researchers/).
CYP2C19-clopidogrel project
The most common implementation among institutions was
CYP2C19 genotyping to predict clopidogrel response and
guide antiplatelet therapy after percutaneous coronary inter-
vention (PCI). The CYP2C19 enzyme has a critical role in
the biotransformation of clopidogrel to its pharmacologically
active form. Approximately 30% of Whites and Blacks and
65% of Asians carry a nonfunctional CYP2C19 gene variant
associated with reduced clopidogrel bioactivation and an
increased risk of major adverse cardiovascular events in
clopidogrel-treated patients after PCI.4 The US Food and
Drug Administration-approved clopidogrel label includes
a boxed warning regarding reduced clopidogrel effective-
ness in poor metabolizers, who have two nonfunctional
alleles. CPIC recommends alternative antiplatelet therapy
after acute coronary syndrome and PCI in poor metabo-
lizers as well as intermediate metabolizers, who have one
nonfunctional allele.4
Institutions vary in their approaches to CYP2C19 imple-
mentation, including timing of genotyping (e.g., preemptively
before antiplatelet therapy is needed or reactively in response
to an order for clopidogrel) and how genotype-based recom-
mendations are communicated to prescribers (e.g., through
automated clinical decision support or personal communi-
cation). However, all institutions are conducting genotyping
in a Clinical Laboratory Improvement Amendments-certified
laboratory, with results entered into the electronic health
record (EHR). In addition, all institutions recommend alter-
native therapy (e.g., prasugrel or ticagrelor) for patients
with genotypes predicting the poor and/or intermediate
metabolizer phenotypes.
A clinical trial examining outcomes with CYP2C19
genotype-guided therapy after PCI is ongoing (Clinicaltri-
als.gov identifier NCT01742117) but not expected to be
completed until 2020. Given the magnitude and expense
of conducting traditional randomized controlled trials for
every pharmacogenetically relevant drug–gene pair, other
approaches are needed to generate the evidence base on
outcomes with pharmacogenetic testing. As such, there was
an interest among groups in collaborating to collect and
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Table 1 Gene–drug pairs implemented into clinical practice at institutions participating in the IGNITE Pharmacogenetics Working Group
Institution Gene–drug pairs implemented
University of Floridaa CYP2C19-clopidogrel; CYP2D6-codeine, tramadol; TPMT-thiopurines;
CYP2D6/CYP2C19-SSRIs; CYP2C19-PPIs; CYP2C19-voriconazole (in
development)
Vanderbilt Universitya CYP2C19-clopidogrel; SLCO1B1-simvastatin; CYP2C9/VKORC1-warfarin;
CYP3A5-tacrolimus; TPMT-thiopurines
Indiana Universitya CYP2C19-clopidogrel, voriconazole, PPIs, citalopram; CYP2D6-opioids, SSRIs,
aripiprazole, atomoxetine; SLCO1B1-simvastatin;
CYP2C9/VKORC1/CYP4F2-warfarin; CYP3A5-tacrolimus; TPMT-thiopurines;
CYP2D6/CYP2C19-TCAs; DPYD-5-fluorouracil, capecitabine, tegafur;
G6PD-rasburicase; ITPA-thioguanine; CYP2B6-efavirenz
Sanford Healtha CYP2C19-clopidogrel; CYP2C9/VKORC1-warfarin; CYP2D6/CYP2C19-SSRIs,
TCAs; CYP2D6-opioids; CYP3A5-tacrolimus; SLCO1B1-simvastatin;
TPMT-thiopurines; DPYD-capecitabine, fluorouracil, tegafur
University of Marylandb CYP2C19-clopidogrel
Mount Sinaib CYP2C19-clopidogrel; CYP2C9/VKORC1-warfarin; SLCO1B1-simvastatin;
CYP2D6-codeine, tramadol; CYP2D6/CYP2C19-TCAs (in development);
CYP2D6/SSRIs (in development)
Duke Universityb SLCO1B1-statins
University of North Carolina at Chapel Hill CYP2C19-clopidogrel
Nemours Children’s Health System CYP2C19-PPIs
University of Illinois at Chicago CYP2C19-clopidogrel; CYP2C9/VKORC1-warfarin
Mission Health System HLA-B*1502-carbamazepine
St. Luke’s Mountain States Tumor Institute DPYD-fluorouracil, capecitabine; TPMT-thiopurines
University of Pittsburgh CYP2C19-clopidogrel
University of Pennsylvania CYP2C19-clopidogrel
H. Lee Moffitt Cancer Center & Research Institute CYP2C19-voriconazole; CYP2D6-opioids; TPMT-thiopurines
University of Alabama, Birmingham CYP2C19-clopidogrel
PPI, proton pump inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
aFunded within IGNITE Network for pharmacogenetics implementation.
bFunded within IGNITE for disease susceptibility genomic implementation, but also conducting pharmacogenetics implementation.
share data on cardiovascular outcomes with implementation
of CYP2C19 genotype-guided therapy after PCI as our first
demonstration project.
Each institution obtained approval from their respective
Institutional Review Board (IRB) prior to data collection and
sharing. A common data collection tool, adapted from the
International Clopidogrel Pharmacogenomics Consortium,
was developed to facilitate data collection and aggregation.
Data were collected manually at each site, deidentified,
and sent to UF for aggregation. The process for developing
the tool included identifying all variables that would be
ideally collected from the EHR to comprehensively assess
outcomes among patients who underwent PCI and received
CYP2C19 genotyping. The tool was pilot-tested at several
institutions to ensure that each data element was clearly
defined and evaluate the feasibility of collecting different
data elements of interest. The revised tool includes 60
variables, including patient characteristics, medical history,
PCI indication, genotype results, antiplatelet therapy, and
cardiovascular events within 12 months of PCI, and is
freely available through the IGNITE website SPARK toolbox
(https://ignite-genomics.org/spark-toolbox/researchers/).
The tool can be modified and serve as a foundation to
facilitate harmonized data collection on future projects.
Data from the initial working group collaboration, including
1,815 patients who underwent PCI and CYP2C19 genotyp-
ing across seven sites, were presented as a late-breaking
abstract at the 2016 American Heart Association Scientific
Sessions.5 These data showed that among patients with a
nonfunctional allele, the risk for major adverse cardiovas-
cular events was significantly higher when clopidogrel vs.
alternative antiplatelet therapy was prescribed.
ADDITIONAL COLLABORATIVE RESEARCH
OPPORTUNITIES
The CYP2C19-clopidogrel outcomes project serves as
the initial example of a multiinstitution collaborative effort
to examine outcomes with real-world pharmacogenetic
implementation. It also provides the platform for future
studies, including those with other gene–drug pairs. This
includes an ongoing project to compare implementation
strategies for CYP2C19-guided antiplatelet therapy across
sites and assess how various strategies impact metrics.
Further, because outcomes for multiple drugs are influenced
by CYP2C19 genotype, IGNITE serves as a platform for
standardizing our approach to pleiotropy, the principle that
variation in one pharmacogene can impact outcome for
more than one drug.6 In this regard, some of our member
institutions provide automated decision support for selective
serotonin reuptake inhibitors and other relevant drugs in
patients who have had CYP2C19 initially genotyped for
clopidogrel.6 Another important principle in pharmacogenet-
ics is that biotransformation is robust, and the metabolism
of one drug is often influenced by more than one gene. This
makes the case for testing multiple genes, and many of our
www.cts-journal.com
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member institutions are therefore moving toward genotyping
multiplexed panels of pharmacogenes. This provides the
opportunity for groups to share data to examine the benefits
of multiplex pharmacogenetics testing.
The IGNITE Pharmacogenetics Working Group also pro-
vides the infrastructure to examine economic outcomes with
practical implementation of pharmacogenetics, and an eco-
nomic analysis of CYP2C19-guided antiplatelet therapy is
underway. Cost-effectiveness analysis can impact decisions
by providers to adopt pharmacogenetic testing, by payers
to reimburse for such companion diagnostics, and by reg-
ulatory agencies when deciding on what guidance to issue
regarding such technology. These decisions, in turn, impact
the likelihood that high-value pharmacogenetic testing will
be implemented outside of research settings. Additional
sensitivity analysis can be used to explore the impact of
apparent unexplained variation in costs and outcomes, and
to identify priorities for future research, while complementary
decision analytic models can be used to explore hetero-
geneity of costs and effects across time, patient groups, and
clinical settings. Thus, the coordination of analyses across
sites provides an opportunity not only to provide statistically
more precise estimates for use in economic modeling, but
also to better understand how results generalize across
different implementation strategies for dissemination of
pharmacogenetics test results in real-world settings.
SUMMARY
In summary, we have created a multiinstitution infrastruc-
ture of academic and community healthcare institutions
with a shared interest in advancing the practice of phar-
macogenetics. Recognizing the paucity of data on clini-
cal utility of genotype-guided therapy, the working group
aims to provide data on important clinical and economic
outcomes with pharmacogenetic implementation, with the
ultimate goal of providing evidence to support reimburse-
ment for testing and broader clinical implementation of
pharmacogenetics.
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